Clinical Trial Update: A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of TP-0184 for anemia in adults with IPSS-R low or intermediate-risk myelodysplastic syndromes was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• TP-0184

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Anemia in Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-30